A Tijuana, Mexico-based cancer treatment facility, Oasis of Hope has treated more than 100,000 patients from around the world. Directed by Dr. Francisco Contreras, Oasis of Hope provides state-of-the-art cancer treatments in combination with research-based cancer-fighting nutrient therapies.
Thursday, July 1, 2021
How Vitamin K3 Improves Cancer Therapy
Thursday, June 17, 2021
Positive Experience at Oasis of Hope
Oasis of Hope is a hospital in Tijuana, Mexico, that combines conventional allopathic approaches with complementary alternative therapies that enhance effectiveness in fighting cancer. Working with cancer patients from around the world, Oasis of Hope is known for its leading-edge perspective on the treatment of cases thought incurable.
Tuesday, March 23, 2021
Emotional Care in Fighting Cancer
Emphasizing social activities such as sing-alongs and supportive conversation, Dr. Contreras takes impetus from US medical studies that have found that argumentative people often survive longer. Boiled down into a life-affirming credo, he clearly states this as “people who are more determined, beat it.” With patient stays typically lasting three weeks, foundational principles exercised throughout are those of “Do no harm” and “Treat the patient as yourself.”
Friday, June 12, 2020
Science Validates “Whole Person” Approach to Cancer Treatment
At Oasis of Hope Hospital in Tijuana, Mexico, patients from all over the world have taken advantage of an integrative, complementary system of alternative medicine that has achieved significantly high survival rates for a range of common Stage 4 cancers. Oasis of Hope’s clinically supported approach is anchored first in doing no harm by avoiding the over-use of aggressive conventional therapies. It is additionally centered on treating the whole person - body, mind, and spirit.
The hospital’s philosophy puts individual patients, their families, and their quality of physical and spiritual life first when preparing any treatment plan. This outlook has won broad support over recent years, even within the conventional medical community. Physicians have begun to recognize that it is impossible to treat a tumor in isolation: Since disease affects the whole person, treatment must involve the whole person as well.
To give one example: In December 2016, the journal Integrative Cancer Therapies published an article noting the success of whole-person approaches, advocating for new systems that support ways of integrating each patient’s emotional, psychological, social, and existential needs in treatment. The article’s authors additionally noted that plans designed to support healthy lifestyle changes, among other factors, contributed to the overall success of cancer treatment in the groups studied.
Additionally, the American Cancer Society lists on its website a number of types of practitioners able to treat patients with cancer. The list includes professions, such as osteopathy, that focus on the “whole person” approach to care.
Monday, November 20, 2017
Active Hexose Correlated Compound - Boosting the Immune System
Oasis of Hope Hospital is a Tijuana institution that focuses solely on eliminating cancer through a holistic range of therapies. Oasis of Hope physicians possess extensive knowledge, which includes the use of nutraceuticals for controlling cancer. Among those actively used is active hexose correlated compound (AHCC), which is extracted from a number of mushroom types.
The extracts possess both antitumor and immunomodulation properties and are effective in strengthening the immune system. This is particularly critical for patients who are undergoing chemotherapy, which severely impacts the immune system. Through the use of AHCC, the immune system is protected. In addition to restoring the depressed immune system, it is effective in reversing the effects cancer cells produced immunosuppressive factors. It also boosts the activity of healthy killer cells that target cancer cells.
AHCC’s benefits extend to decreasing radiotherapy side effects and reducing nausea and anxiety while boosting appetite. Its effects are similar to melatonin in that it also stimulates the system of immune surveillance that acts as a sentinel against cancer.
Thursday, November 9, 2017
Gerson Therapy Uses Natural Approach to Treat Chronic Diseases
Oasis of Hope offers cancer care and treatment through a multidisciplinary team of physicians that combine conventional and alternative methods for a comprehensive patient experience. Based in Tijuana, Mexico, Oasis of Hope also supports Cancer Aid and Research Fund, an organization that collaborates with a range of leading alternate cancer resources.
Cancer Aid and Research Fund promotes the use of the Gerson Therapy, a holistic and natural approach to treating chronic debilitating illnesses. Patients of the Gerson Therapy follow a natural wellness regimen that stimulates the body’s ability to heal itself.
According to Gerson Therapy physicians, an organic diet of plant-based food, raw juices, coffee enemas, and natural supplements boosts the patient’s immune system, allowing it to treat the toxicity and nutritional deficiencies that cause many degenerative diseases. The increased supply of enzymes, nutrients, and minerals also helps break down diseased tissues.
Dr. Max Gerson developed the treatment in the 1930s and over the course of 30 years refined it through empirical observations and careful experimentation. His daughter Charlotte continued his research after his death in 1959 and later established the Gerson Institute to enhance Gerson Therapy protocols.
Monday, October 30, 2017
Erbitux and Rituxan - Drug Treatments for Addressing Specific Cancers
Located in Tijuana and emphasizing integrative therapy pathways to treat cancer, Oasis of Hope offers treatments ranging from epigenetics to insulin potentiation chemotherapy. Oasis of Hope also provides access to leading-edge drug therapies, including those involving the administration of erbitux and rituxan.
The latter drug is employed in treating B-cell non-Hodgkin’s lymphoma and stands as the first FDA-approved cancer fighting therapeutic monoclonal antibody. This relatively recent therapy approach targets CD20 antigens on both malignant and normal B-Cells. This type of white blood cell lymphocyte is essential in producing antibodies. While the immune system naturally attacks and eliminates marked B-cells, it does not attack the young stem cells in the bone marrow which do not possess the CD20 antigen. This enables the regeneration of healthy B-cells following treatment.
Erbitux is used to address neck, head, and colorectal cancers through targeting malignant cells that contain the epidermal growth factor receptor (EGFR). Inhibiting the activity of EGFR, erbitux selectively blocks signals that generate cancerous growth and also triggers an immune response against these cells.





